David Kennedy, MD
Ophthalmology · Metairie, LANPI 1518258755
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations.
Across 217 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$987
- Alcon$972
- AbbVie$497
- Tarsus Pharmaceuticals, Inc.$392
- Biotissue Holdings Inc.$317
- Rxsight Inc$272
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,33998%
- Education$801%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 26 | $987 |
| Alcon | 50 | $972 |
| AbbVie(2 entities) | 28 | $497 |
| Tarsus Pharmaceuticals, Inc. | 24 | $392 |
| Biotissue Holdings Inc. | 10 | $317 |
| Rxsight Inc | 3 | $272 |
| Dompe US, Inc. | 9 | $248 |
| Oyster Point Pharma, Inc. | 8 | $215 |
| Carl Zeiss Meditec USA, Inc. | 1 | $206 |
| Mallinckrodt Hospital Products Inc. | 6 | $164 |
| Lumenis BE Inc | 1 | $157 |
| Novartis | 5 | $145 |
| Bausch & Lomb Americas Inc. | 8 | $138 |
| Sun Pharmaceutical Industries Inc. | 8 | $135 |
| Eyevance Pharmaceuticals LLC | 7 | $101 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $91 |
| Harrow Eye, LLC | 3 | $75 |
| Ocular Therapeutix, Inc. | 4 | $66 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $59 |
| Aerie Pharmaceuticals, Inc. | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 2 | $31 |
| Coopervision Inc. | 2 | $30 |
| Shire North American Group Inc | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Amgen | 1 | $17 |
| NEW World Medical,inc. | 1 | $17 |
| Heidelberg Engineering, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$255
- RXSIGHT INJECTOR HANDPIECE$255
- RXSIGHT INJECTOR CARTRIDGE$255
- LIGHT ADJUSTABLE LENS (LAL)$255
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$255
- KXL System$254
- CIRRUS 5000$206
- Prokera$164
- AmnioGraft$164
- AmnioGuard$164
- optilight$157
- KXL1B-CE-marked KXLsystem$143
- Clareon$140
- Clareon PanOptix Pro$138
- XDEMVY$122
- iStent inject W$111
- Photrexa$111
How this compares
$5,438 in reported general payments places this provider in the 80th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 123 | $102,543 |
| XdemvyLotilaner | 15 | $28,652 |
| XiidraLifitegrast | 32 | $26,118 |
| LumiganBimatoprost | 58 | $25,865 |
| Prednisolone Acetate | 562 | $18,444 |
| VyzultaLatanoprostene Bunod | 21 | $7,552 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $5,069 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $5,063 |
| ValacyclovirValacyclovir Hcl | 80 | $4,974 |
| Latanoprost | 560 | $4,224 |
| Ofloxacin | 320 | $3,786 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $2,893 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 199 | $2,784 |
| Timolol Maleate | 113 | $2,197 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 15 | $2,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $497 | $133,477200 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $138 | $33,66953 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $392 | $28,65215 claims |
| AlconSimbrinza | $972 | $5,06321 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $59 | $1,86015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Metairie
- Ethan SternMetairie$16K
- John FrisbeeMetairie$14K
- Benjamin GuidryMetairie$9K
- Scott LanouxMetairie$8K
- Tyler GoffMetairie$7K
- John BoyleMetairie$7K
- Nicholas FrisardMetairie$7K
- Brandon DavisMetairie$7K
- Henry HaleyMetairie$7K
- Owen LacourMetairie$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.